Space-Based Drug Manufacturing: Questions and Answers on Varda's Commercial Orbit Plans

As space becomes more accessible, companies are exploring the potential of manufacturing drugs in orbit. Varda Space Industries, a startup from El Segundo, California, has taken a significant step by partnering with pharmaceutical company United Therapeutics. This collaboration aims to leverage microgravity to create novel crystal forms of existing drugs, potentially improving their stability and efficacy. Below, we answer key questions about this innovative approach to drug development.

1. What is Varda Space Industries' plan for drug manufacturing in space?

Varda Space Industries aims to provide a commercial, repeatable platform for producing drug molecules in microgravity. The company has signed an agreement with United Therapeutics to send versions of the pharmaceutical firm's drugs into orbit. Once in space, these drugs are allowed to form solid crystals under weightless conditions. The absence of gravity means that surface tension dominates, leading to unique atomic arrangements that cannot be replicated on Earth. The hope is that these space-grown crystals will yield new drug versions with improved properties such as enhanced stability, solubility, or potency. Varda's chief strategy officer, Michael Reilly, describes this as the first commercial pathway for products made in space, marking a shift from government-funded experiments on the International Space Station to private-sector initiatives.

2. How does microgravity affect the crystallization of drugs?

On Earth, gravity influences how molecules settle and arrange themselves during crystallization. In microgravity, however, gravitational forces are negligible, and surface tension becomes the dominant force. For example, water forms a wobbly sphere in orbit instead of flowing downward. This altered environment allows chemical mixtures to behave differently, enabling crystals to grow in more uniform and less defected structures. For pharmaceutical companies, this is valuable because the atomic arrangement of a drug's crystals directly impacts its stability, dissolution rate, and bioavailability. By growing crystals in space, researchers may discover polymorphs—different crystal forms—that don't occur naturally on Earth. These new forms could lead to drugs that last longer, are easier to absorb, or have fewer side effects. Varda's process involves launching raw materials, allowing crystallization to occur in orbit, and then returning the finished crystals to Earth for analysis and potential commercialization.

3. Who is United Therapeutics, and why are they interested in space manufacturing?

United Therapeutics is a biopharmaceutical company led by CEO Martine Rothblatt. Rothblatt has a background in satellite communications, having worked on early telecommunications satellites, and later built a multibillion-dollar health franchise. The company specializes in drugs for pulmonary arterial hypertension (PAH), a lung disease that Rothblatt's daughter suffers from, as well as a subsidiary that develops genetically modified pigs for organ transplantation. United has a history of reformulating its blockbuster drugs to extend patent life and stay ahead of generic competition—for example, switching from oral pills to inhaled versions. Rothblatt sees space as a potential next frontier for creating “even more amazing” versions of existing drugs. By partnering with Varda, United hopes to explore orbital conditions that may yield superior crystal forms, thereby enhancing their product portfolio and maintaining a competitive edge.

4. What is the business model behind space-based drug reformulation?

The pharmaceutical industry often relies on reformulation to keep blockbuster drugs relevant. By creating improved versions—such as changing delivery methods or finding new crystal forms—companies can secure additional patents and fend off generic rivals. Specialist firms like Halozyme and MannKind assist drugmakers in this process using terrestrial technologies like nebulizers or nanoparticles. Varda aims to enter this market by offering a space-based alternative: sending raw drug compounds into orbit, processing them in microgravity to form new crystals, and returning the enhanced products to Earth. The model depends on rocket launches becoming frequent and affordable enough to make the round-trip economically viable. Varda was founded in 2021 by Delian Asparouhov of Peter Thiel's Founders Fund and Will Bruey, a former SpaceX engineer. They believe that as launch costs drop, space manufacturing will transition from experimental to commercial, enabling a steady business of in-orbit reformulation with potential royalties on future drug sales.

5. Who founded Varda Space Industries and what is their background?

Varda Space Industries was founded in 2021 by Delian Asparouhov and Will Bruey. Asparouhov is a partner at Founders Fund, the venture capital firm led by billionaire Peter Thiel, and has a keen interest in space technology investments. Bruey previously worked as an avionics engineer at Elon Musk's SpaceX, where he gained firsthand experience in spacecraft design and launch operations. Their complementary backgrounds—Asparouhov's venture capital insight and Bruey's engineering expertise—positioned them to identify an opportunity in space manufacturing. They bet that the growing frequency and declining cost of rocket launches would make it feasible to send materials to orbit, process them, and bring them back. Bruey now serves as Varda's CEO, leading the company's efforts to commercialize in-orbit drug production. Their vision aligns with the broader trend of making space accessible for industrial applications beyond telecommunications and Earth observation.

6. What are the main challenges for commercial drug manufacturing in orbit?

While the concept of making drugs in space is promising, several challenges remain. First, cost: despite decreasing launch expenses, sending payloads to orbit and returning them is still expensive compared to terrestrial manufacturing. The business model relies on sustained reductions in launch costs, which are not guaranteed. Second, regulatory hurdles: drugs produced in space must meet the same safety and efficacy standards set by agencies like the FDA. The unique environment may raise questions about consistency, contamination, and scalability. Third, technical limitations: microgravity crystallization can be unpredictable, and not all drugs will benefit from space conditions. Varda must demonstrate that the process yields reproducible results with commercial value. Finally, competition from terrestrial reformulation methods—such as nanocrystals or amorphous solid dispersions—may offer similar benefits at lower cost. Overcoming these challenges will require not only technological success but also strategic partnerships with pharmaceutical companies like United Therapeutics to validate the approach.

7. How does this compare to previous space-based drug experiments?

Prior efforts to conduct drug experiments in space have primarily been small-scale, government-funded projects aboard the International Space Station (ISS). These experiments often focused on fundamental science, such as understanding how proteins crystallize in microgravity, rather than on producing commercial drug products. The ISS environment is limited in capacity, scheduling, and the ability to return products quickly. Varda's approach is different: they plan dedicated missions with the explicit goal of manufacturing and returning drugs for commercial use. By building their own reentry capsules and leveraging private launch providers, they aim for repeatable, cost-effective operations. This represents a transition from academic curiosity to a potential industry. If successful, Varda and United Therapeutics could pave the way for other pharmaceutical companies to explore orbital manufacturing, opening a new chapter in space commercialization.